|Bid||47.1900 x 1200|
|Ask||47.2000 x 1400|
|Day's Range||46.6600 - 47.3900|
|52 Week Range||46.4900 - 71.8600|
|Beta (3Y Monthly)||0.16|
|PE Ratio (TTM)||8.38|
|Earnings Date||Jan 30, 2019 - Feb 4, 2019|
|Forward Dividend & Yield||3.20 (6.55%)|
|1y Target Est||57.95|
Altria Group, Inc. (Altria) (MO) will host a live audio webcast on Thursday, January 31, 2019, at 9:00 a.m. Eastern Time to discuss its 2018 fourth-quarter and full-year business results. Altria will issue a press release containing its business results at approximately 7:00 a.m. Eastern Time the same day. The webcast can be accessed at altria.com or through the Altria Investor App.
KELOWNA, British Columbia, Jan. 17, 2019 -- via NetworkWire -- Lexaria Nicotine LLC, a wholly owned subsidiary of Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX), has entered.
NEW YORK, Jan. 17, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
# Altria Group Inc ### NYSE:MO View full report here! ## Summary * Perception of the company's creditworthiness is negative * Bearish sentiment is low * Economic output in this company's sector is expanding ## Bearish sentiment Short interest | Positive Short interest is extremely low for MO with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting MO. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $15.58 billion over the last one-month into ETFs that hold MO are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Positive According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Consumer Goods sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. ## Credit worthiness Credit default swap | Negative The current level displays a negative indicator. MO credit default swap spreads are near their highest levels for the past 1 year, which indicates the market's more negative perception of the company's credit worthiness. Please send all inquiries related to the report to email@example.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Altria Group Inc., Liberty Global, Diplomat Pharmacy Inc. and Cyanotech Corp have declined to their respective three-year lows
Many tend to ignore consumer stocks not oriented toward the latest technology. Consumers and investors tend to focus on companies that produce new gadgets or bring the next wave of tech innovation. Many "boring" consumer stocks that have less of a tech focus, however, offer an impressive track record with dividends. This serves as an advantage over a tech industry, which tends to lag the S&P 500 when it comes to offering dividend stocks. Due in large part to dividends and a loyal customer base, consumer stocks tend to offer stability lacking in some of these more exciting stocks. Also, contrary to popular belief, many of these companies have become innovation leaders. Although the press may not always report it, these firms often pioneer new products that place them on the cutting edge in their industries. InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 A-Rated Stocks to Buy That The Smart Money Is Piling Into The following three companies lead this innovation. They also offer growth rates, valuations and dividend yields that should draw the attention of stock buyers. Source: Shutterstock ### AbbVie (ABBV) Admittedly, AbbVie (NYSE:ABBV) has made a few of my stock lists. I had hoped not to write about ABBV for that reason. However, when an equity offers an almost single-digit forward price-to-earnings (P/E) ratio, double-digit profit growth and the third-highest dividend yield among dividend aristocrats, I cannot leave it off in good conscience. ABBV stock trades a perfect storm for buyers. The patent on Humira faces patent expirations across the world. This has inspired a wave of selling in AbbVie. Despite this, analysts believe the company's drug pipeline will keep profits growing at double-digit rates. This has led to a forward PE ratio that stands at about 10.1. This perfect storm also applies to the firm's payouts. Due to its previous history as part of Abbott Laboratories (NYSE:ABT), ABBV holds dividend aristocrat status. When a stock hikes its payout for 46 years as AbbVie has, the stock price depends heavily on keeping this streak alive. Even better, ABBV has not made not offered a token hike in the payout merely to maintain the dividend aristocrat status. AbbVie went further, taking the payout from $2.56 per share in 2017 to $3.59 per share in 2018 to $4.28 per share this year. Approving such hikes when they face intense pressure to raise the payout every year shows a strong belief in its own future. Considering the low P/E ratio, the profit levels, and the dividend growth amounts, ABBV becomes one of the more obvious choices among consumer stocks. Source: Peyri Herrera via Flickr (Modified) ### Altria Group (MO) Few consumer stocks reflect resilience better than Altria (NYSE:MO). This year will mark 55 years since the U.S. Surgeon General released their report warning on the dangers of smoking. Amid anti-smoking campaigns, increasing tobacco taxes, and multi-billion dollar legal settlements, MO stock should have sunk into obscurity. Instead, Altria has become an unlikely success story. Despite the hostile environment for tobacco, the company continues to find opportunity. Currently, it invests in both smokeless tobacco and alcohol. It currently holds a 10.2% stake in Anheuser Busch-InBev (NYSE:BUD), for example. Also, despite legal barriers, it has also turned to the emerging marijuana sector. In late 2018, Altria purchased a 45% stake in Cronos (NASDAQ:CRON) for $1.8 billion. Even with the hostile business environment, MO stock manages to maintain a generous dividend. The current dividend of $3.20 per share yields almost 6.6%. Although MO does not hold dividend aristocrat status, the payout has increased in most years. As a result, MO stock has long remained a dividend powerhouse. Those who bought the equity in 2000 and reinvested the dividends receive their original investment back every year in dividends alone. The same holds true for those who bought in 1985 and spent or invested the payouts elsewhere. The company also looks attractive from a valuation and growth perspective. The forward P/E stands at 11.3. Moreover, analysts predict a 7.5% profit growth rate this year. Also, they expect those profit increases to remain in the high-single-digits for years to come. With its successes in related business, and its ability to maintain growth despite strong anti-tobacco sentiment, Altria should continue to stand out among consumer stocks. Source: Shutterstock ### General Mills (GIS) Despite producing recession-proof products, General Mills (NYSE:GIS) and its direct peers have endured years of struggle. An increasing interest in fresh and organic foods has diminished demand for the packaged foods General Mills has produced. As a result, it has seen both revenue and profits steadily fall over the last few years. This has taken GIS stock to levels first seen in 2012. However, a turnaround could occur soon. General Mills has begun to pivot to reflect consumer tastes. The company owns brands such as Cascadian Farm, Larabar, and Muir Glen that produce certified organic foods. Such products have helped revenues and profits turns around. After years of falling numbers, analysts predict a 5.5% increase in profits next year. Revenues have already begun to improve as Wall Street expects a 7.7% increase in sales growth for this year. Also, due to the years of decline, GIS stock trades at 12.7 forward earnings. Although this would not impress investors in a shrinking business, it begins to appear reasonable with growth returning. Also, with a five-year average P/E of 20.6, investors will likely enjoy a nice gain by waiting for the multiple to return to its long-term average. Even better for income-oriented investors, the $1.96 per share dividend yields around 4.75%. Since they have achieved a 15-year streak of dividend increases, another payout hike will likely come this year. Both consumers and investors have waited a long time for packaged food companies to embrace more natural foods. General Mills has finally made that move. With its attractive valuations and dividend yields, GIS stock should find a place among the more attractive high-dividend consumer stocks. As of this writing, Will Healy did not hold a position in any of the aforementioned stocks. You can follow Will on Twitter at @HealyWriting. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks You Can Set and Forget (Even In This Market) * 10 Virtual Assistants for the Future of Smart Homes * 7 5G Stocks to Buy as the Race for Spectrum Tightens Compare Brokers The post 3 Back-of-the-Shelf Consumer Stocks With Growth and Income appeared first on InvestorPlace.
SINGAPORE (AP) — Asian markets were mostly lower Thursday as U.S. and Chinese officials wrapped up three days of talks in Beijing without significant breakthroughs.
Aphria (NYSE:APHA) is slated to report its fiscal second-quarter earnings on Friday morning. Few reports in my recent memory - for any stock, not just Aphria stock - have been more important. The numbers alone could have a huge impact on APHA stock. The marijuana sector is still in its early stages. Every company in the space is growing exponentially, off of small bases. APHA needs to keep pace with its competitors, particularly as its rivals like Cronos Group (NASDAQ:CRON) and Canopy Growth (NYSE:CGC) receive multi-billion-dollar cash infusions from larger players. But the results, as important as they are, might be the least important aspect of the Q2 report. The company still hasn't responded to short-seller allegations, made over a month ago, that tanked Aphria stock. And it's facing a hostile takeover effort from new - and smaller - marijuana producer Green Growth Brands (OTCQB:GGBXF). InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Stocks You Can Set and Forget (Even In This Market) All told, there will be a lot of information to analyze on Friday, and Aphria stock is likely to be volatile on that day and going forward. I called Aphria's earnings one of three key reports to watch this week, but that understates the case. This almost certainly is the most important report in Aphria's history, and it might be the most important report in the history of the entire pot sector. ### The Short Sellers of Aphria Stock In early December, Hindenburg Investment Research and Quintessential Capital Management published an article alleging "that Aphria's acquisitions of assets in Latin America constituted "'self-dealing.'" Aphria stock had fallen ahead of the report, due in part to sector-wide weakness, but it dropped even further on the release. At one point, Aphria stock fell 50% below its previous value. Aphria stock has recovered some of its losses, and there has been some good news on the Latin American front, as a Bloomberg reporter toured some of Aphria's assets last month in Jamaica and Latin America and highlighted "plastic tubs brimming with medical-grade marijuana." As a result, the assertion that Aphria's overseas operations are worthless and/or a fraud seems to have been weakened. But investors no doubt are waiting for more color on the value of those assets and the prices that APHA paid for them. In other words, they want the company to - per a promise that it previously made - issue a more detailed rebuttal than it released in the wake of the short sellers' report. It's possible that APHA's more comprehensive response will be issued on Friday or that at least the issue will be discussed in detail during the company's earnings conference call. How management addresses these claims will not just be important for APHA stock. Investors in CRON, CGC, Aurora Cannabis (NYSE:ACB), Tilray (NASDAQ:TLRY), and every other pot stock need to pay close attention to this issue as well. This is a new sector, and a number of pot companies have inexperienced managers and are or were listed on the pink sheets. So the space still needs more credibility. Aphria can add to the sector's credibility or undermine it. ### The Buyout Offer Aphria's credibility is important not just for retail investors, but because its integrity could help determine whether additional big players decide to enter the sector. After Altria (NYSE:MO) and Constellation Brands (NYSE:STZ,STZ.B) invested in cannabis companies, investors began wondering who would be the next target. Luke Lango argued that it would be Aphria. But that won't happen if Aphria's management can't fully dispel the allegations regarding its acquisitions. And in the meantime, Aphria has another offer on its hands from Green Growth. As Lango pointed out, the offer itself doesn't seem to make a lot of sense. But it will be interesting to see how Aphria's management reacts to the offer. Will APHA let slip that it might be interested in another offer from, say, a company with more history and more cash than Green Growth? And how is APHA managing the potential distraction from the hostile bid, which could further dissuade more viable potential acquirers from making an offer, at least in the short term? APHA won't announce on Friday that it has accepted Green Growth's offer. But how the company reacts to the bid will impact investors' appraisal of the credibility of APHA's management. ### The Numbers Finally, there are the actual results. And those will be an important driver of Aphria stock, too. Aphria's revenue more than doubled in its fiscal first quarter. After Canada legalized pot in October, investors will be looking for more of the same. Profits aren't all that important: Aphria's EBITDA, which was previously positive, has become negative as it invests more in its business, and that shift makes sense. In a competitive market - particularly with giants now backing two of Aphria's potential competitors - market share will be the key factor in the near-term. Can APHA show that it's one of the market leaders? That's the question from a fundamental standpoint. But it's also the question from a management standpoint. Is this a real company that can create real profits for owners of Aphria stock? That's the question investors in APHA stock - and every other marijuana play - are trying to figure out right now. The information released on Friday will have a huge impact on how investors in Aphria stock answer that question in the coming months. As of this writing, Vince Martin has no positions in any securities mentioned. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Retail Stocks to Buy for Winning the Online Battle * The 7 Best Stocks in the Entrepreneur Index * 7 5G Stocks to Buy as the Race for Spectrum Tightens Compare Brokers The post Aphria's Earnings to Have Major Impact on Aphria Stock, Other Pot Stocks appeared first on InvestorPlace.
When many investors think of Dow Jones Industrial Average components, they picture old companies which produce everyday products. Although people may still buy their brands, these Dow stocks are thought to generate little excitement. That might have rightly described the Dow Jones stocks of past decades. However, even the allegedly stodgy Dow Jones has undergone change. Companies such as Alcoa (NYSE:AA) or Altria (NYSE:MO) have long since given way to the likes of Microsoft (NASDAQ:MSFT) and Nike (NYSE:NKE). While some older-line industrial companies remain, other Dow components lead the latest revolution in tech and will likely remain some of the best stocks available today. * 9 A-Rated Safety Stocks for a Grossly Oversold Market Some even trade at levels that should draw interest from investors. The following seven Dow Jones stocks to invest in now lead innovation in their fields and trade at levels attractive to buyers: InvestorPlace - Stock Market News, Stock Advice & Trading Tips ### Chevron (CVX) Source: swong95765 via Flickr (Modified) Some might view Chevron (NYSE:CVX) as a strange choice. Although oil prices have bounced off of the lows of late December, one cannot escape the fact that oil prices have fallen by about 35% from their early October highs. Given this challenge, investors can understand why CVX stock has flirted with bear market territory in recent days. However, Chevron operates in all segments of the industry. Hence, it can still turn profits from refining and retail sales even if oil prices do not rise quickly. Also, after falling into bear market territory around Christmas, CVX stock has staged an 11% recovery in just two weeks. Today, it trades at about 15% below its 52-week high. This forward price-to-earnings ratio of 14 seems typical for this stock. However, income-oriented investors should take an interest in the dividend. Chevron set this year's payout at $4.48 per share. Also, the yield of about 4% comes in at around double the S&P 500 average payout. It has also increased this payout for 32 straight years, proving its stability in both booms and busts. Yes, the dividend coupled with a modest P/E ratio make CVX seem like a stereotypical Dow equity. However, for investors wanting a growing source of cash flow now and equity appreciation later, few choices will surpass CVX stock. ### Disney (DIS) Source: Shutterstock Disney (NYSE:DIS) suffered for years as cable cutting hurt profits coming from the Disney Channel and ESPN. Even though DIS stock began to feel the pain from that in 2015, the effects have lingered. Fortunately, that appears poised to turn around. Finally, the company has begun to address lost revenues from its declining cable television channels. Disney has gone all-in on streaming, having already launched ESPN+ and introducing Disney+ later this year. When Disney+ launches, it will take content, and likely a large portion of market share, from Netflix (NASDAQ:NFLX). Moreover, the latest report indicates growth in every division except Consumer Products and Interactive Media. The Studio Entertainment division earned a 157% increase in income. Profits from Parks & Resorts increased by 11%. Even the struggling Media Networks division increased by 4%. Also, the company further bolstered its top-rated content library by buying assets from Twenty-First Century Fox (NASDAQ:FOXA, NASDAQ:FOX). This should more than offset disappointments in the Lucasfilm division. * 10 Oversold Stocks Due for a Bounce DIS stock currently trades at about $111 per share. It has spent four years stuck in a range. However, with the catalysts brought by Disney+, ESPN+, and its ever-improving content library, DIS could become one of the better-performing Dow stocks in 2019. ### Intel (INTC) Source: Shutterstock Like a few Dow Jones stocks, the year 2018 has become one Intel (NASDAQ:INTC) investors would like to forget. Security threats, a sudden CEO departure and competition from the likes of Nvidia (NASDAQ:NVDA) and Advanced Micro Devices (NASDAQ:AMD) weighed on Intel stock. However, despite these issues, it has also avoided some of the problems that have plagued their peers. Intel did not involve itself in the crypto industry. Moreover, since the slump in tech stocks began, INTC stock has fallen by less than 10%. Both NVDA and AMD lost half their value in the same period. To be sure, a glut of available chips has hurt the sector in general. However, the forward P/E of around 10 may explain why investors were unwilling to sell further. This creates a chance for an upward move as the industry works off the surplus in chips. Moreover, Intel has moved on from the PC era. The data center business will likely become larger than the PC business in the next few years. Also, the adoption of 5G wireless should bolster its Internet of Things (IoT) division and the automotive division it co-opted when it purchased Mobileye. As a result, analysts expect double-digit profit growth to return in 2019. Between the low multiple and these industry catalysts, Intel stock should finally see a long-awaited recovery. ### Pfizer (PFE) Source: Shutterstock Many investors feel Pfizer (NYSE:PFE) has traded like other stereotypical Dow Jones stocks. It has struggled over the last few years as one-time blockbuster drugs faced expiring patents. However, the company has long maintained a robust pipeline. As a result, new drugs such as Eliquis and Ibrance have emerged to replace revenue lost from Lyrica and Viagra. This has helped to bring back investors to PFE stock. After failing to breach the mid-$30s-per-share range for years, Pfizer stock surged, reaching a peak of about $46 per share by the end of November. While it has fallen off since that time, it remains above the previous range. One factor that likely helped PFE is a reorganization announced during the summer. The company will create divisions centered around innovative medicines, established medicines and consumer healthcare. The company may also spin off the consumer healthcare division. Many credit that proposed spinoff with the higher stock price. * 10 Top Stock Picks From the Street's Best Analysts Company financials may have helped as well. Its forward P/E of 14.1 comes in well below its average multiple in recent years of 22.2. Pfizer also recently increased its annual dividend for 2019 to $1.44 per share. This takes the yield to almost 3.3% and will mark the ninth straight year of payout hikes. Hence, buying PFE stock at these levels offers a revitalized organization along with appealing valuations for new buyers. ### Verizon (VZ) Source: Shutterstock As the only major telco among Dow Jones stocks, Verizon (NYSE:VZ) finds itself in a unique position. VZ stock stagnated for the last five years as intense competition in its wireless business weighed on profit margins. To make things worse, competition forced Verizon to spend tens of billions of dollars on a 5G network buildout to remain a relevant player in wireless. However, that large, painful investment could finally pay off for VZ stock. Along with T-Mobile (NASDAQ:TMUS) and former Dow Jones stock AT&T (NYSE:T), it will likely emerge as one of the three companies to own a 5G network. This will drive the tech industry in the near term as autonomous cars, IoT and possibly many technologies not yet invented will depend on Verizon's network. This could break VZ stock out of its range. Even after a recent sell-off, Verizon stock trades less than 10% below the all-time high set amid the tech bubble in 1999. However, with a forward P/E of around 12, it has reached this price at a more sustainable valuation. Also, its dividend of $2.41 per share yields around 4.2%. It has also risen every year since 2007. Between its generous, increasing payout and its importance to the tech industry, VZ stock looks poised among its Dow Jones stocks peers to return to a growth trajectory. ### Walgreens Boots Alliance (WBA) Source: Mike Mozart via Flickr As the newest of the Dow stocks, Walgreens (NASDAQ:WBA) suddenly finds itself struggling. Amazon (NASDAQ:AMZN) has entered this market, something that drew fear in other retail segments. Also, with archrival CVS (NYSE:CVS) purchasing Aetna, many will question whether Walgreens now operates at a disadvantage. WBA stock also saw a massive sell-off following the latest earnings report. While the company beat estimates and announced cost cuts, sales declines in the important U.K. market hurt the stock. However, Walgreens has countered the CVS threat by allying with Alphabet (NASDAQ:GOOGL, NASDAQ:GOOG) and Humana (NYSE:HUM). Also, in its U.S. market, it benefits from 10,000 people per day aging into Medicare and enrolling in drug plans. Its 9,600 or so drug stores across all 50 states position the company to benefit from this large population segment moving into Medicare. Moreover, the stock has traded in a range since 2014. As a result, its forward P/E has fallen to 10.1, well under half of the stock's five-year average. Furthermore, it has taken the dividend yield to almost 2.5%. Fortunately, the recent financial woes pose no danger to WBA's 42-year streak of dividend hikes. * 7 Stocks to Sell In January With the recent drop, many will avoid WBA stock. However, with its large market presence and low multiples, investors should consider viewing the decline as a sale on one of the sector's best stocks and not a reason to panic. ### Exxon Mobil Corporation (XOM) Source: Mike Mozart via Flickr (Modified) As its most direct peer, the case for Exxon Mobil (NYSE:XOM) mirrors that of Chevron in many respects. Like most oil and gas companies, it has seen its stock decline amid falling oil prices. The ongoing trade war, as well as fears of an economic slowdown, have taken XOM stock into a bear market. However, investors need to remember that XOM participates in all segments of the oil and gas industry. With oil just above $50 per barrel, exploration and production could slow. However, such declines have less effect on divisions involved in refining, chemicals or retail gasoline sales. Moreover, Exxon Mobil produces more natural gas than any other company. A burgeoning liquefied natural gas (LNG) export industry will bring more of Exxon's natural gas to overseas markets. This benefits XOM not only with increased sales, but also with the much higher prices LNG commands in Europe and Asia. Further, few companies match Exxon Mobil regarding stability. Nothing speaks to that stability more than its dividend. Its payout of $3.28 per share yields about 4.75%. Also, the 35-year history of dividend hikes, even in times of rock-bottom oil prices, speaks to its resilience. Such a generous, increasing payout along with its robust business lines makes XOM stock a bargain at 13.9 forward P/E. Due to these factors, it holds its place as one of the more attractive Dow Jones stocks despite falling oil prices. As of this writing, Will Healy did not hold a position in any of the aforementioned stocks. You can follow Will on Twitter at @HealyWriting. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Top Stock Picks From the Street's Best Analysts * 7 Tech Stocks Without China Exposure * 5 Strong-Buy Stocks That Crushed 2018 Compare Brokers The post 7 Dow Jones Stocks Set to Charge Higher appeared first on InvestorPlace.
Inside only a few months, marijuana companies became both a revolution and an unmitigated disaster. Canopy Growth (NYSE:CGC) perfectly demonstrated this wild ebb-and-flow. Last August, CGC stock skyrocketed nearly 72%. But since mid-October, shares melted down, eventually returning to break-even. As things currently stand, Canopy Growth stock presents an intriguing opportunity. On the positive front, CGC benefits broadly from groundbreaking legislative momentum. In 2016, a record number of states voted for legalization to varying degrees. Two years later, several more states joined in on the action. But on the flipside, marijuana stocks operate largely on potential. Depending on timing, this has resulted in untold riches for speculators and steep losses for those who held too long. Plus, in this market environment, relatively few people have the mood to gamble. InvestorPlace - Stock Market News, Stock Advice & Trading Tips * The 7 Best Stocks in the Entrepreneur Index Still, with shares roughly half off from its closing high, it's worth considering all angles. Here are three pros and three cons for CGC stock, starting with the bad news … ### Cons CGC Stock Has Too Much Competition: A few years ago, cannabis firms represented the niche of niche investments. None traded in reputable exchanges, meaning speculators had to resort to over-the-counter exchanges. More critically, you had no idea about what you were really investing. Fast forward to today, and you have several marijuana-related organizations listed in the New York Stock Exchange or the Nasdaq. That raised the profile for the industry, leading to major deals. For instance, tobacco giant Altria Group (NYSE:MO) took a stake in Cronos (NASDAQ:CRON) last month. For the marijuana sector, the deal-making initiatives lend legitimacy. At the same time, partnerships such as the one between CGC and Constellation Brands (NYSE:STZ) are no longer unique. The low-hanging fruit is gone, which means buying Canopy Growth stock now attracts more risk. Legislative Momentum Is a Double-Edged Sword: One of the biggest news items for CGC stock in December was the farm bill, which in part called for hemp legalization. With the domestic agricultural industry under fire due to the ongoing trade war, President Trump signed the measure. This represented an extremely rare demonstration of bipartisan politics. More importantly, both conservatives and liberals tacitly agreed that marijuana legalization is an economic issue. With several states suffering budgetary issues, cannabis offers a viable solution. Moreover, the farm bill aligns with the growing trend of high-profile Republicans and Democrats finding consensus on a previously contentious issue. But like almost anything in this sector, this positive development cuts both ways. The farm bill will eventually open the door for anyone to grow weed. Not that I would know, but marijuana is relatively easy to cultivate. This leads to saturation, which would present a headwind for Canopy Growth stock. Where's the Beef? Although the legal cannabis industry is still in the early phases, I mentioned that the low-hanging fruit is gone. Certainly, Wall Street has moved past the introductory stage. It's no longer enough merely to upload a pretty website. Increasingly, investors want to see substance. When Canada became the first G7 member state to legalize recreational weed, the novelty effect faded quickly. The positive news had to directly bolster individual cannabis firms. When that didn't happen, shareholders panicked. This dynamic presents challenges for CGC stock. If you look at the underlying company's financials, they don't stand out. While it's not fair to compare cannabis stocks with "normal" investments, most prospective buyers want something to chew on. What does Canopy Growth stock give you? Currently, an okay balance sheet and iffy profitability and growth metrics. ### Pros CGC Makes Smart Acquisitions: For any company, acquisitions are tough to assess properly. Usually a positive indicator, expansionary efforts nevertheless carry risks. Primarily, management can overpay for an asset that doesn't deliver expected returns. However, with CGC, I'm confident in the leadership team's strategy and vision. In a relatively quiet and underappreciated announcement, Canopy bought out Storz & Bickel in an all-cash transaction. As a marijuana vaporizer company, Storz & Bickel provides significant retail exposure for CGC stock. But it's not just the retail element that piqued my interest. The German manufacturer is a renowned name among cannabis connoisseurs. Famous for its Volcano Digital Vaporizer, Storz & Bickel specializes in premium-quality products that deliver pure aromatics. With the base product and associated accessories, customers can expect to pay upwards of $500 or more. The best part? They're paying it. Like its backer, Constellation Brands, CGC emphasizes quality over quantity. Their Storz & Bickel buyout further solidifies this ethos. Canopy Offers Competitive Differentiation: The push for quality products doesn't just bring CGC stock into a better light compared to the competition. Moving forward, this strategy will determine whether the company can keep the lights on. As I previously mentioned, the farm bill bolsters the entire cannabis industry, turning an illegal venture into a legitimate one. But if everyone jumps on board, the net profit in the weed business will be severely limited. That's because the barrier to entry is very low. While I'm not suggesting that growing marijuana is a braindead activity, it doesn't take much: all you really need is some land, cannabis seeds and a conducive environment. Should marijuana truly go mainstream, CGC will advantage its cannabidiol (CBD) and cannabis-extract business. CBD is what separates the contenders from the pretenders. This is the arena where top manufacturers can extract unique cannabis strains that address specific ailments or symptoms. Such products marry technology with botany, an avenue for which underfunded newcomers won't have an answer. Canopy Growth Stock Has Stabilized: Finally, risk-tolerant buyers should consider the technical argument for CGC stock. Like almost every other name in weed, Canopy has taken a beatdown over the past three months. At the same time, I think the negativity is overdone. While many questions remain concerning the burgeoning sector, the bottom line is that all indicators point toward broader acceptance. At a time when no one can agree on anything, everyone agrees on marijuana legalization. Although it's possible that weed stocks can crumble from here on out, it's highly unlikely. The demand is too strong. Coincidentally, Canopy Growth stock has finally stabilized. Of course, this doesn't guarantee anything. But after a near-50% haircut, it's reasonably safe to assume most of the bad news is baked in. As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Stocks to Buy Down 20% in December * 5 Chinese Stocks to Avoid Now (But Buy Later) * 3 Big Gainers That Easily Could Be the Best Stocks to Buy Compare Brokers The post Canopy Growth Stock: 3 Pros, 3 Cons appeared first on InvestorPlace.
# Altria Group Inc ### NYSE:MO View full report here! ## Summary * Perception of the company's creditworthiness is negative * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding ## Bearish sentiment Short interest | Positive Short interest is extremely low for MO with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting MO. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, growth of ETFs holding MO is favorable, with net inflows of $23.19 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. ## Economic sentiment PMI by IHS Markit | Positive According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Consumer Goods sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. ## Credit worthiness Credit default swap | Negative The current level displays a negative indicator. MO credit default swap spreads are near their highest levels for the past 1 year, which indicates the market's more negative perception of the company's credit worthiness. Please send all inquiries related to the report to firstname.lastname@example.org. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.